Race Oncology partners with George Clinical for RC220 bisantrene trials

Proactive - Interviews for investors

Race Oncology Ltd (ASX:RAC) chief medical officer Dr Michelle Rashford joins Proactive’s Meagan Evans to discuss the appointment of global contract research organisation George Clinical International to support the clinical development of its RC220 bisantrene as a cardioprotective and anticancer treatment in solid tumour patients. This decision followed an extensive selection process by Race Oncology's clinical team. Dr Rashford expressed enthusiasm for the partnership, highlighting George Clinical's responsiveness and clinical insight. The Phase 1a/1b trial will target advanced solid tumour patients in Australia, Hong Kong and South Korea, focusing on those indicated for doxorubicin treatment. The study aims to deliver human safety and pharmacokinetic data, determine optimal dosing with doxorubicin and gather initial human results on the cardioprotective, anti-cancer and m6A RNA activity of RC220 bisantrene. George Clinical was chosen for its extensive trial experience and successful track record in oncology trials across multiple regions. The trial will be conducted in two stages across multiple sites, employing a Bayesian design for flexibility and speed. The Phase 1a stage will assess safety, tolerability, pharmacokinetics, m6A RNA effects and the maximum tolerated dose. The Phase 1b stage will evaluate the optimal dosage of RC220 bisantrene in combination with doxorubicin. The trial's final protocol and commencement are pending human ethics and institutional approvals. Race Oncology has begun engagement with George Clinical under a Start-Up Agreement (SUA) valued at A$1,071,067, with further payments under a master service agreement (MSA) as key milestones are achieved. The estimated total cost of the Phase 1 trial is A$6 million. #ProactiveInvestors #RaceOncology #ASX #GeorgeClinical, #RC220Bisantrene, #CardioprotectiveTreatment, #AnticancerTreatment, #ClinicalTrials, #OncologyResearch, #SolidTumours, #CancerTreatment #biotech #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews